Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
29 studies found for:    " November 21, 2011":" December 21, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers
Condition: HIV Infections
Interventions: Biological: HIV-MAG (3,000mcg);   Biological: GENEVAX® IL-12 (100mcg);   Biological: GENEVAX® IL-12 (1000mcg);   Biological: Ad35-GRIN/ENV
2 Completed Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence
Condition: HIV Infection
Interventions: Drug: Immediate ARV treatment initiation with TDF/FTC/EFV;   Other: South African recommendation guided ARV (TDF/FTC/EFV) initiation
3 Recruiting Use of Incentives to Retain Drug Users in HIV Therapy
Condition: HIV Infection
Intervention: Other: monetary reinforcer
4 Withdrawn Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant Women
Condition: HIV Infections
Interventions: Drug: 1% tenofovir gel;   Drug: Placebo gel
5 Active, not recruiting Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C);   Biological: rAd5 env A;   Biological: rAd5 env B;   Biological: rAd5 env C;   Biological: rAd5 gag-pol;   Biological: Placebo Vaccine
6 Completed
Has Results
Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: E/C/F/TDF;   Drug: E/C/F/TAF Placebo;   Drug: E/C/F/TAF;   Drug: E/C/F/TDF Placebo
7 Completed
Has Results
Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: NNRTI;   Drug: FTC/TDF;   Drug: Stribild
8 Completed Early HIV Therapy in Patients With High CD4 Cell Counts
Condition: HIV
Interventions: Drug: Standard ART;   Drug: Study-Provided ART
9 Active, not recruiting Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women
Conditions: HIV Infections;   Tuberculosis
Interventions: Drug: Isoniazid (INH);   Drug: Placebo for isoniazid (INH)
10 Recruiting Evaluation of a Tailored Virtual Intervention to Empower Persons Living With HIV for Therapy Self-management
Condition: HIV
Intervention: Behavioral: VIH-TAVIE
11 Terminated Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Condition: HIV-1 Infection
Interventions: Drug: BMS-986001;   Drug: Placebo matching with BMS-986001;   Drug: Efavirenz;   Drug: Lamivudine;   Drug: Tenofovir
12 Completed Men of African American Legacy Empowering Self
Condition: HIV
Interventions: Behavioral: Men of African American Legacy Empowering Self;   Behavioral: Standard HIV Education & Risk Reduction
13 Completed American Ginseng to Improve HIV-Associated Fatigue: A Randomized, Placebo-Controlled, Parallel Design, Multiple-Dose Clinical Trial
Condition: HIV/AIDS-associated Fatigue
Interventions: Drug: American ginseng;   Dietary Supplement: Placebo for American ginseng
14 Completed
Has Results
Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
Conditions: HIV Infections;   Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN);   Drug: Ribavirin (RBV);   Drug: Boceprevir (BOC)
15 Completed
Has Results
A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: Dolutegravir
16 Completed Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: Ortho-Cyclen;   Drug: Dolutegravir;   Drug: Placebo
17 Completed Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors
Condition: HIV-1 Infection
Interventions: Drug: Isentress® (Raltegravir, 400 mg every 12 hours);   Drug: Isentress® (Raltegravir, 400 every 12 hours)
18 Active, not recruiting A Smoking Cessation Trial in HIV-infected Patients in South Africa
Conditions: Smoking Cessation;   HIV
Interventions: Drug: Nicotine;   Behavioral: Intensive Counseling
19 Active, not recruiting Lipopeptide Immunisation With GTU-multiHIV Trial
Condition: HIV-1 Infection
Interventions: Biological: Placebos of GTU-multiHIV B and LIPO-5 vaccines;   Biological: GTU-multHIV B vaccine and LIPO-5 vaccine
20 Completed Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men
Conditions: Human Immunodeficiency Virus Infection;   Sexually Transmitted Diseases
Interventions: Behavioral: Men Making a Difference HIV/STD Risk Reduction Intervention;   Behavioral: Health Promotion Control

   Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.